Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of neuronal nicotinic receptors (NNR) Therapeutics for the treatment of multiple diseases and disorders of the central nervous system. The Company has clinical-stage product candidates for... more

CuraGen Corporation (CuraGen) is a biopharmaceutical development company engaged in developing therapeutics for the treatment of cancer. The Company is focused on advancing its cancer treatments, belinostat and CR011-vcMMAE, through clinical development and toward commercialization. In... more

Tranzyme Pharma is developing a number of mechanism-based therapeutics for the treatment of gastrointestinal (GI) and metabolic diseases. GI and metabolic diseases are characterized by large, underserved markets with few or poorly performing drugs for most indications. The Company is... more

GenVec, Inc. (GenVec) is a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer. As of December 31, 2007, TNFerade was the subject of a... more

EntreMed, Inc. (EntreMed) is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells and the blood vessels that nourish them. The Company focused on developing drugs that are safe and convenient, and provide the potential for... more

Sunesis Pharmaceuticals, Inc. (Sunesis) is a clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of small molecule therapeutics for use in oncology and other diseases. As of December 31, 2007, the Company was advancing three... more

Peregrine Pharmaceuticals, Inc. (Peregrine) is a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection. The Company is advancing three separate clinical programs with its compounds bavituximab and Cotara... more

Avalon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Its lead product candidate, AVN944, an inosine monophosphate dehydrogenase (IMPDH) inhibitor, is in Phase II clinical development.... more

TOPIGEN is developing several new classes of drugs and is actively progressing two drug candidates in Phase II trials for COPD and asthma. These drugs are uniquely focused on inhibiting multiple inflammation targets underlying the chronic pulmonary diseases. TOPIGEN also has a number of... more

Celsion Corporation is a biotechnology company focused on developing drugs for the treatment of various cancer indications. The first of these development projects involves ThermoDox, a heat activated liposome containing doxorubicin. The Company plans to develop ThermoDox for multiple... more

Demegen develops natural and novel peptides for the treatment or prevention of infections due to multi-drug resistant bacteria and fungi. The Company's lead products address important unmet medical needs. Applications under development include dermatological, vaginal, respiratory,... more

AlphaRx is developing several drug products in the therapeutic categories of Osteoarthritis and Infectious Disease. AlphaRx intends to file IND and NDA submissions with the FDA (when necessary) and license these products to other pharmaceutical companies for worldwide commercialization. ... more

Nastech is a clinical stage biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products based on our proprietary molecular biology-based drug delivery technologies and our proprietary ribonucleic acid interference technology. Nastech and... more

CEL-SCI Corporation is engaged in the development of a product called Multikine for the treatment of cancer. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted, it is the cancer immunotherapy that both kills cancer... more

Inhibitex, Inc. is a biopharmaceutical company focused on the development of differentiated anti-infective products. It pursues pre-clinical or clinical-stage antiviral development programs via in-licensing or acquisition. On September 19, 2007, the Company completed the acquisition of... more

We are a clinical-stage biopharmaceutical company that uses our patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a novel technology that genetically transforms the... more

Immusol is a private biotechnology company located in San Diego, California. The company currently employs approximately 50 employees, 90% of whom are focused on Research and Development. Immusol has built a management team with considerable combined experience in drug discovery and... more

Athersys, Inc. is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates. In July 2007, the Company initiated a Phase I clinical trial in the United Kingdom with its lead candidate in clinical development, ATHX-105, for the treatment of... more

D-Pharm (www.dpharm.com) is a biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich product pipeline from its drug targeting and discovery technologies, Regulated Activation of Prodrugs (D-RAPTM) and Membrane Active Chelators (MAC). The... more

Corautus Genetics Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative gene therapy products for the treatment of cardiovascular and vascular disease. Corautus is currently developing and testing a gene therapy product using the Vascular... more

GlycoDesign is currently developing ATH in preclinical studies as a therapeutic for the prevention of neurocognitive deficits during cardiopulmonary bypass surgery. The Company plans to partner with device companies to develop ATH as an antithrombotic coating on catheters used for... more

Rexahn Pharmaceuticals, Inc. (Rexahn) is development-stage biopharmaceutical company focused on the discovery, development, and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction and other medical needs. Rexahn is developing targeted... more

We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

Santaris Pharma is a pioneer in the field of oligonucleotide drugs based on the third generation RNA chemistry, Locked Nucleic Acid (LNA), to which the company holds worldwide exclusive rights in therapeutics. Amongst several unique features, the LNA chemistry enables the development of... more

EnVivo Pharmaceuticals (located in Watertown, MA) is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system (CNS), currently focusing on Alzheimer's disease, Parkinson's disease, Huntington's disease, and... more

Evolutec is an investment company under AIM Rules pending any further transaction. Evolutec was originally founded as a biopharmaceutical company with the intention of developing novel therapeutic products from natural biological sources. Initial success was not borne out by larger... more

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system. Using its ProCellEx system, the Company is developing a pipeline of recombinant therapeutic... more

BioXell SpA is an Italy-based biopharmaceutical company. The Company focuses on the research, development and commercialization of therapies for various medical needs. It is active in a range of therapeutic areas, such as urology (benign prostatic hyperplasia, overactive bladder and male... more

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The Company seeks to develop versatile product candidates each capable... more

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. While much of the attention in the medical community has been focused on resistance in gram-positive pathogens such... more

Dynogen is a clinical stage biopharmaceutical company developing more effective treatments for gastrointestinal (GI) and genitourinary (GU) disorders. The Company has an advanced pipeline of clinical development programs focused on attractive and untapped markets in disease areas that... more

Viron Therapeutics is a clinical stage biopharmaceutical company developing a completely new class of anti-inflammatory therapeutics to treat and prevent human inflammatory disorders. Viron's novel approach to drug development is based on the use of viral proteins as a source of... more

Aphton Corporation, headquartered in Philadelphia, Pennsylvania is a clinical stage biopharmaceutical company focused on developing targeted immunotherapies for cancer and other diseases. The Company's products seek to neutralize hormones involved in the growth and proliferation of... more

Ambrx, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common twenty,... more

ITEM 1. BUSINESS Overview Zonagen, Inc. (“the Company”, “Zonagen,” or “we,” “us” or “our”) was organized on August 28, 1987 and is a development stage company. We are a biopharmaceutical company focused on the development of new... more

Ester Neurosciences is developing a unique, disease-modifying approach to combat neurological disorders that result from disrupted acetlycholinesterase (AChE) neuromodulation. "Cholinergic mechanisms represent a basic pathophysiological pathway underlying neurodeterioration that is... more

Milkhaus, fortified by the numerous scientific patents it holds, is devoting itself to providing products designed to enhance urological health, skin care, wound care, and address other healthcare concerns.

AM-Pharma is a biopharmaceutical company, based in Bunnik, The Netherlands. The company is focused on the pre-clinical and clinical development of novel therapeutics to treat inflammatory diseases and infectious diseases. All our products address high medical needs and commercially... more

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats.... more

Bayhill Therapeutics Inc. is focused on the translation of research into therapeutics by developing novel drugs for the treatment of autoimmune diseases. The company has established a product platform of antigen-specific therapeutics, BHT-DNA, with broad potential applications in treating... more

Collgard Biopharmaceuticals, the tissue therapeutics company, is developing drug treatments that target disease progression by directly influencing the tissue regeneration process. Central to Collgard's novel approach is its lead drug candidate, Tempostatin (Halofuginone hydrobromide).... more

InteKrin Therapeutics, Inc. is a privately-held biopharmaceutical company based in Los Altos, CA pursuing the clinical development of therapeutics for diabetes, obesity and metabolic disorders. The company focuses on high value therapeutics addressing significant unmet medical needs in... more

Launched in December of 1996, Phytomedics is a privately owned Company that operates from its corporate headquarters in Jamesburg, NJ. Most of the Company's R&D takes place at the Biotech Center at Rutgers University, under the leadership of Dr. Ilya Raskin, a Company co-founder.... more

Cytheris is a privately held company founded in January 1999. In April 1999, the company signed an exclusive worldwide in-licensing agreement on the basic patents protecting Interleukin-7 (IL-7). In July 2002, we completed our B Series of venture financing for around EUR 7 millions... more

Ascenta Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, with a clinical trials management office in Malvern, Pennsylvania and a research and development subsidiary in Shanghai, China. Our company is dedicated to the discovery and... more

NovaBay Pharnaceuticals, Inc. (NovaBay) is a clinical stage biopharmaceutical company focused on developing product candidates for the treatment or prevention of different infections in hospital and non-hospital environments. The Company has discovered and is developing a class of... more

ReceptoPharm, Inc. maintains collaborative and research relationships with a number of noted academic researchers associated with the National Institutes of Health (NIH), Harvard University, Massachusetts General Hospital, Yale University, Stanford University, Baylor College of Medicine,... more

NovaCal Pharmaceuticals is a clinical-stage pharmaceutical company developing a new class of compounds: The AganocideÔ compounds. They are novel, safe and effective non-antibiotic antimicrobial molecules. Our goals are two-fold: 1) to reduce the threat of hospital-based infections, and 2)... more

Jennerex is a clinical stage company focused on the discovery and the development of targeted cancer therapeutics. Jennerex intends to enter into both development and commercialization alliances with partners to bring the first-in-class cancer therapeutics to patients world-wide. ... more

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets.